Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant

Jennifer Richmond, Alissa Robbins, Kathryn Evans, Dominik Beck, Raushan T. Kurmasheva, Catherine A. Billups, Hernan Carol, Sue Heatley, Rosemary Sutton, Glenn M. Marshall, Deborah White, John Pimanda, Peter J Houghton, Malcolm A. Smith, Richard B. Lock

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Ph-like acute lymphoblastic leukemia (ALL) is a genetically defined high-risk ALL subtype with a generally poor prognosis. In this study, we evaluated the efficacy of birinapant, a small-molecule mimetic of the apoptotic regulator SMAC, against a diverse set of ALL subtypes. Birinapant exhibited potent and selective cytotoxicity against B-cell precursor ALL (BCP-ALL) cells that were cultured ex vivo or in vivo as patient-derived tumor xenografts (PDX). Cytotoxicity was consistently most acute in Ph-like BCP-ALL. Unbiased gene expression analysis of BCP-ALL PDX specimens identified a 68-gene signature associated with birinapant sensitivity, including an enrichment for genes involved in inflammatory response, hematopoiesis, and cell death pathways. All Ph-like PDXs analyzed clustered within this 68-gene classifier. Mechanistically, birinapant sensitivity was associated with expression of TNF receptor TNFR1 and was abrogated by interfering with the TNFα/TNFR1 interaction. In combination therapy, birinapant enhanced the in vivo efficacy of an induction-type regimen of vincristine, dexamethasone, and L-asparaginase against Ph-like ALL xenografts, offering a preclinical rationale to further evaluate this SMAC mimetic for BCP-ALL treatment.

Original languageEnglish (US)
Pages (from-to)4579-4591
Number of pages13
JournalCancer Research
Volume76
Issue number15
DOIs
StatePublished - Aug 1 2016

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
B-Lymphoid Precursor Cells
Heterografts
Receptors, Tumor Necrosis Factor, Type I
Genes
Asparaginase
Tumor Necrosis Factor Receptors
Hematopoiesis
Vincristine
Dexamethasone
Cultured Cells
Neoplasms
Cell Death
birinapant
Gene Expression
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Richmond, J., Robbins, A., Evans, K., Beck, D., Kurmasheva, R. T., Billups, C. A., ... Lock, R. B. (2016). Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant. Cancer Research, 76(15), 4579-4591. https://doi.org/10.1158/0008-5472.CAN-16-0523

Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant. / Richmond, Jennifer; Robbins, Alissa; Evans, Kathryn; Beck, Dominik; Kurmasheva, Raushan T.; Billups, Catherine A.; Carol, Hernan; Heatley, Sue; Sutton, Rosemary; Marshall, Glenn M.; White, Deborah; Pimanda, John; Houghton, Peter J; Smith, Malcolm A.; Lock, Richard B.

In: Cancer Research, Vol. 76, No. 15, 01.08.2016, p. 4579-4591.

Research output: Contribution to journalArticle

Richmond, J, Robbins, A, Evans, K, Beck, D, Kurmasheva, RT, Billups, CA, Carol, H, Heatley, S, Sutton, R, Marshall, GM, White, D, Pimanda, J, Houghton, PJ, Smith, MA & Lock, RB 2016, 'Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant', Cancer Research, vol. 76, no. 15, pp. 4579-4591. https://doi.org/10.1158/0008-5472.CAN-16-0523
Richmond J, Robbins A, Evans K, Beck D, Kurmasheva RT, Billups CA et al. Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant. Cancer Research. 2016 Aug 1;76(15):4579-4591. https://doi.org/10.1158/0008-5472.CAN-16-0523
Richmond, Jennifer ; Robbins, Alissa ; Evans, Kathryn ; Beck, Dominik ; Kurmasheva, Raushan T. ; Billups, Catherine A. ; Carol, Hernan ; Heatley, Sue ; Sutton, Rosemary ; Marshall, Glenn M. ; White, Deborah ; Pimanda, John ; Houghton, Peter J ; Smith, Malcolm A. ; Lock, Richard B. / Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant. In: Cancer Research. 2016 ; Vol. 76, No. 15. pp. 4579-4591.
@article{d698cd199e964fd7b7704c3708fa4da0,
title = "Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant",
abstract = "Ph-like acute lymphoblastic leukemia (ALL) is a genetically defined high-risk ALL subtype with a generally poor prognosis. In this study, we evaluated the efficacy of birinapant, a small-molecule mimetic of the apoptotic regulator SMAC, against a diverse set of ALL subtypes. Birinapant exhibited potent and selective cytotoxicity against B-cell precursor ALL (BCP-ALL) cells that were cultured ex vivo or in vivo as patient-derived tumor xenografts (PDX). Cytotoxicity was consistently most acute in Ph-like BCP-ALL. Unbiased gene expression analysis of BCP-ALL PDX specimens identified a 68-gene signature associated with birinapant sensitivity, including an enrichment for genes involved in inflammatory response, hematopoiesis, and cell death pathways. All Ph-like PDXs analyzed clustered within this 68-gene classifier. Mechanistically, birinapant sensitivity was associated with expression of TNF receptor TNFR1 and was abrogated by interfering with the TNFα/TNFR1 interaction. In combination therapy, birinapant enhanced the in vivo efficacy of an induction-type regimen of vincristine, dexamethasone, and L-asparaginase against Ph-like ALL xenografts, offering a preclinical rationale to further evaluate this SMAC mimetic for BCP-ALL treatment.",
author = "Jennifer Richmond and Alissa Robbins and Kathryn Evans and Dominik Beck and Kurmasheva, {Raushan T.} and Billups, {Catherine A.} and Hernan Carol and Sue Heatley and Rosemary Sutton and Marshall, {Glenn M.} and Deborah White and John Pimanda and Houghton, {Peter J} and Smith, {Malcolm A.} and Lock, {Richard B.}",
year = "2016",
month = "8",
day = "1",
doi = "10.1158/0008-5472.CAN-16-0523",
language = "English (US)",
volume = "76",
pages = "4579--4591",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "15",

}

TY - JOUR

T1 - Acute sensitivity of Ph-like acute lymphoblastic leukemia to the SMAC-mimetic birinapant

AU - Richmond, Jennifer

AU - Robbins, Alissa

AU - Evans, Kathryn

AU - Beck, Dominik

AU - Kurmasheva, Raushan T.

AU - Billups, Catherine A.

AU - Carol, Hernan

AU - Heatley, Sue

AU - Sutton, Rosemary

AU - Marshall, Glenn M.

AU - White, Deborah

AU - Pimanda, John

AU - Houghton, Peter J

AU - Smith, Malcolm A.

AU - Lock, Richard B.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Ph-like acute lymphoblastic leukemia (ALL) is a genetically defined high-risk ALL subtype with a generally poor prognosis. In this study, we evaluated the efficacy of birinapant, a small-molecule mimetic of the apoptotic regulator SMAC, against a diverse set of ALL subtypes. Birinapant exhibited potent and selective cytotoxicity against B-cell precursor ALL (BCP-ALL) cells that were cultured ex vivo or in vivo as patient-derived tumor xenografts (PDX). Cytotoxicity was consistently most acute in Ph-like BCP-ALL. Unbiased gene expression analysis of BCP-ALL PDX specimens identified a 68-gene signature associated with birinapant sensitivity, including an enrichment for genes involved in inflammatory response, hematopoiesis, and cell death pathways. All Ph-like PDXs analyzed clustered within this 68-gene classifier. Mechanistically, birinapant sensitivity was associated with expression of TNF receptor TNFR1 and was abrogated by interfering with the TNFα/TNFR1 interaction. In combination therapy, birinapant enhanced the in vivo efficacy of an induction-type regimen of vincristine, dexamethasone, and L-asparaginase against Ph-like ALL xenografts, offering a preclinical rationale to further evaluate this SMAC mimetic for BCP-ALL treatment.

AB - Ph-like acute lymphoblastic leukemia (ALL) is a genetically defined high-risk ALL subtype with a generally poor prognosis. In this study, we evaluated the efficacy of birinapant, a small-molecule mimetic of the apoptotic regulator SMAC, against a diverse set of ALL subtypes. Birinapant exhibited potent and selective cytotoxicity against B-cell precursor ALL (BCP-ALL) cells that were cultured ex vivo or in vivo as patient-derived tumor xenografts (PDX). Cytotoxicity was consistently most acute in Ph-like BCP-ALL. Unbiased gene expression analysis of BCP-ALL PDX specimens identified a 68-gene signature associated with birinapant sensitivity, including an enrichment for genes involved in inflammatory response, hematopoiesis, and cell death pathways. All Ph-like PDXs analyzed clustered within this 68-gene classifier. Mechanistically, birinapant sensitivity was associated with expression of TNF receptor TNFR1 and was abrogated by interfering with the TNFα/TNFR1 interaction. In combination therapy, birinapant enhanced the in vivo efficacy of an induction-type regimen of vincristine, dexamethasone, and L-asparaginase against Ph-like ALL xenografts, offering a preclinical rationale to further evaluate this SMAC mimetic for BCP-ALL treatment.

UR - http://www.scopus.com/inward/record.url?scp=84982734852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982734852&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-16-0523

DO - 10.1158/0008-5472.CAN-16-0523

M3 - Article

VL - 76

SP - 4579

EP - 4591

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 15

ER -